Fig. 1From: The association between pulmonary embolism and the cancer-related genomic alterations in patients with NSCLCThe comparison of PE incidence among the NSCLC patients with different results of molecular tests. Note: ALK: Anaplastic Lymphoma Kinase; ROS1: C-Ros Oncogene 1 Receptor Tyrosine Kinase; EGFR: Epidermal Growth Factor Receptor; BRAF: B-Rapidly Accelerated Fibrosarcoma; PD-L1: Programmed Cell Death 1-Ligand 1Back to article page